Financial Performance - Revenues for 2025 were $27.5 million, a decrease of $14.3 million, or 34%, from $41.8 million in 2024, primarily due to a lower number of units sold (70 in 2025 vs. 115 in 2024) and reduced sales to the largest customer[142]. - Gross profit in 2025 was $11.9 million, or 43.3% of revenue, down $12.5 million, or 51%, from $24.4 million, or 58.4% of revenue in 2024, driven by lower sales and higher servicing costs[144]. - Net loss for 2025 was $7.7 million, compared to a net income of $6.6 million in 2024, resulting in a net income per share of $(0.47) for 2025[141]. Operating Expenses - Operating expenses increased to $22.2 million in 2025, up $5.8 million, or 35%, from $16.3 million in 2024, with significant increases in research and development expenses by $3.6 million, or 86%[145][146]. Cash and Receivables - Cash and cash equivalents remained stable at $22.1 million as of December 31, 2025, unchanged from the previous year[147]. - Accounts receivable decreased by $13.7 million, or 70%, to $6.0 million in 2025, primarily due to reduced sales[148]. Inventory and Future Expectations - Inventories increased by $4.5 million, or 44%, to $14.6 million in 2025, reflecting anticipation of future sales growth[148]. - The company expects to return to profitability in 2026 by increasing sales and managing operational expenses, despite uncertainties such as decreased demand from the largest customer and inflation[138]. - Research and development expenses are expected to be substantially lower in 2026 compared to 2025, as the company focuses on product development and reimbursement lobbying costs[146]. Cash Flow - The company reported net cash provided by operating activities of $0.5 million in 2025, contrasting with a net cash used of $0.8 million in 2024[153].

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Full year revenues for 2025 were $27.5 million, down from $41.8 million in 2024, driven by reduced sales to the largest customer [16] - Gross profit for Q4 2025 was $1.9 million, or 38.8% of revenues, compared to $7.1 million, or 54.2% in Q4 2024 [14] - Net loss for Q4 2025 was $3.2 million, or a loss of $0.19 per share, compared to net income of $1.5 million, or $0.09 per diluted share in Q4 2024 [15] - Full year net loss for 2025 was $7.7 million, or a loss of $0.47 per share, compared to net income of $6.6 million, or $0.41 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, with no sales to the largest customer [5][22] - Utilization across the Fair Deal Agreement program increased substantially, with treatments up more than eightfold year-over-year and the number of patients treated increasing by over 250% [6] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia, particularly in Taiwan and South Korea [7][28] - The company expects international markets to remain a significant part of its growth strategy, with Brazil clearance anticipated in 2026 [28] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technology is expected to enhance physician reimbursement and support broader adoption [4][20] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [8][19] - A disciplined approach to scaling the sales organization is being implemented, with plans to hire additional sales representatives [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with greater clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company is focused on educating physicians about the new reimbursement codes to drive adoption and growth [5][8] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents, unchanged from the previous year, and no outstanding debt [18] - Research and development expenses for 2025 increased to $7.8 million, primarily due to higher costs related to billing and reimbursement efforts [17] Q&A Session Summary Question: Guidance on revenue growth excluding the largest customer - Management confirmed that projections for 2026 do not include expectations from the largest customer, as they are reevaluating their model moving forward [22][23] Question: Update on TDI and FDA approval - Management indicated ongoing efforts with the FDA regarding TDI but could not provide a timeline for approval [25] Question: International demand outlook - Management highlighted strong demand in China and growth in Taiwan, with expectations for further expansion in Asia and South America [27][28] Question: Reaction to reimbursement and system mix - Management noted a shift towards outright purchases and leasing options due to improved reimbursement clarity, with a stronger focus on SRT technology [37][41] Question: Interest from private equity-backed groups - Increased interest from private equity groups was noted, with a reevaluation of acquisition strategies due to clearer reimbursement pathways [42]

Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Full year revenues for 2025 were $27.5 million, down from $41.8 million in 2024, driven by reduced sales to the largest customer [16] - Gross profit for Q4 2025 was $1.9 million (38.8% of revenues), compared to $7.1 million (54.2% of revenues) in Q4 2024 [14] - Net loss for Q4 2025 was $3.2 million, compared to a net income of $1.5 million in Q4 2024 [15] - Full year net loss for 2025 was $7.7 million, compared to a net income of $6.6 million in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, with no sales to the largest customer [5][22] - Utilization across the Fair Deal Agreement program increased substantially, with treatments up more than eightfold year-over-year [6] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia [7] - The company expects international markets to remain an important part of its growth strategy, particularly in China, Taiwan, and potential markets in the Middle East and South America [8][28] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technology is expected to enhance physician reimbursement and support broader adoption [20] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [8][19] - The commercial model is evolving to include various acquisition options for customers, including outright purchases and leasing [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with greater clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company anticipates that first quarter system shipments will exceed fourth quarter levels, even without contributions from the largest customer [8][19] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents and no outstanding debt [18] - Prepaid inventory was $1.5 million at year-end, down from $3.3 million in 2024, while total inventories increased to $14.6 million [19] Q&A Session Summary Question: Guidance on revenue growth excluding the largest customer - Management confirmed that projections for 2026 do not include expectations from the largest customer, as they are reevaluating their model [22][23] Question: Update on TDI and FDA approval - Management indicated ongoing efforts with the FDA regarding TDI but could not provide a timeline for approval [25] Question: International demand outlook - Management highlighted strong demand in China and growth in Taiwan, with expectations for expansion into other Asian markets and South America [27][28] Question: Reaction to reimbursement and system mix - Management noted a shift towards outright purchases and leasing due to guaranteed reimbursements, with a focus on SRT technology [37][41] Question: Interest from private equity-backed groups - Increased interest from private equity groups was noted, with a reevaluation of acquisition strategies due to clearer reimbursement pathways [42]

Financial Data and Key Metrics Changes - Revenues for Q4 2025 were $4.9 million, a significant decrease from $31 million in Q4 2024, primarily due to lower unit sales [13] - Gross profit for Q4 2025 was $1.9 million, or 38.8% of revenues, down from $7.1 million, or 54.2% in Q4 2024, driven by lower sales and higher servicing costs [14] - For the full year 2025, revenues were $27.5 million, compared to $41.8 million in 2024, reflecting a decrease in unit sales [15] - The net loss for 2025 was $7.7 million, or a loss of $0.47 per share, compared to a net income of $6.6 million, or $0.41 per diluted share in 2024 [18] Business Line Data and Key Metrics Changes - The company shipped 14 units in Q4 2025, with 8 in the U.S. and 6 internationally, but did not include sales to its largest customer [24] - The Fair Deal Agreement program saw substantial year-over-year utilization increases, with treatments up more than eightfold and the number of patients treated increasing by over 250% in 2025 [7] Market Data and Key Metrics Changes - International sales were strong in Q4 2025, with shipments to China and a growing demand in Asia, particularly in Taiwan and South Korea [8][28] - The company expects international markets to remain a significant part of its growth strategy, with Brazil and the Middle East also showing potential [29] Company Strategy and Development Direction - The introduction of new CPT codes for SRT and IG-SRT technologies is expected to enhance physician reimbursement and support broader adoption of non-invasive treatments [4] - The company aims to achieve full-year profitability in 2026, supported by a diversified customer base and expanding international opportunities [9] - A disciplined approach to scaling the sales organization is being implemented, with plans to hire additional sales representatives to enhance market education and lead conversions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with improved clarity and control over the business, emphasizing the positive impact of new reimbursement codes [20] - The company is focused on converting interest into system placements as the year progresses, with expectations for Q1 revenues to exceed Q4 levels [19] Other Important Information - The company ended 2025 with $22.1 million in cash and cash equivalents, with no outstanding debt, indicating a strong balance sheet [18] - Research and development expenses for 2025 increased to $7.8 million, reflecting higher costs related to billing and reimbursement efforts [17] Q&A Session Summary Question: Does the revenue growth guidance for Q1 assume no contribution from the largest customer? - Management confirmed that projections for 2026 exclude expectations from the largest customer, and any contribution from them would be considered upside [24] Question: What is the status of the TDI program and expected FDA approval? - Management indicated ongoing efforts with the FDA but could not provide a timeline for approval [26] Question: What is the demand outlook internationally for 2026? - Management highlighted strong demand in China and growth in Taiwan, with expectations for expansion in South Korea, Japan, and potential entry into Brazil and the Middle East [28][29] Question: How has the reaction to reimbursement affected system mix and financing options? - Management noted a shift towards outright purchases and leasing options due to guaranteed reimbursements, with a stronger focus on SRT products [38][40] Question: What is the outlook for service revenue? - Service revenue remains consistent at about 10% of total revenue, with no expected changes [48]

Financial Performance - Revenues for Q4 2025 were $4.9 million, a decrease from $13.1 million in Q4 2024, primarily due to lower unit sales [6]. - The net loss for Q4 2025 was $3.2 million, or $0.19 per share, compared to a net income of $1.5 million, or $0.09 per diluted share, in Q4 2024 [11]. - Full-year revenues for 2025 were $27.5 million, down from $41.8 million in 2024, driven by reduced sales to the largest customer [14]. - Adjusted EBITDA for 2025 was negative $9.6 million, compared to positive $8.7 million in 2024 [19]. - Net loss for the year ended December 31, 2025, was $7,719,000 compared to a net income of $6,647,000 in 2024, representing a significant turnaround in performance [36]. - The company reported a basic net loss per share of $0.47 for the year ended December 31, 2025, compared to a net income per share of $0.41 in 2024 [36]. Revenue and Sales - The company shipped 14 SRT systems in Q4 2025, up from 6 systems in Q3 2025, excluding shipments to its largest customer [2]. - Total revenues for the three months ended December 31, 2025, were $4,939,000, a decrease from $13,067,000 in the same period of 2024 [36]. Profitability and Gross Profit - Gross profit for 2025 was $11.9 million, or 43.3% of revenue, compared to $24.4 million, or 58.4% of revenue, in 2024 [16]. - Gross profit for the year ended December 31, 2025, was $11,867,000, down from $24,431,000 in 2024, indicating a decline of approximately 51.6% [36]. Expenses - Research and development expenses for 2025 were $7.8 million, up from $4.2 million in 2024, primarily due to increased product development costs [17]. - Operating expenses for the year ended December 31, 2025, totaled $22,174,000, an increase from $16,341,000 in 2024, marking a rise of approximately 35.5% [36]. - Research and development expenses increased to $7,778,000 for the year ended December 31, 2025, compared to $4,216,000 in 2024, indicating a growth of about 84.5% [36]. Assets and Liabilities - Total current assets decreased to $45,892,000 as of December 31, 2025, from $56,738,000 in 2024, reflecting a decline of approximately 19.2% [34]. - Total liabilities decreased to $4,941,000 as of December 31, 2025, from $6,338,000 in 2024, a reduction of about 22% [34]. - Total stockholders' equity decreased to $48,098,000 as of December 31, 2025, from $55,827,000 in 2024, a decline of approximately 13.9% [34]. Cash Position - The company ended 2025 with $22.1 million in cash and cash equivalents and no debt [4]. - Cash and cash equivalents remained relatively stable at $22,083,000 as of December 31, 2025, compared to $22,056,000 in 2024 [34]. Future Outlook - FDA treatments delivered increased significantly in 2025, with over 11,000 treatments to 922 patients, compared to 1,367 treatments to 264 patients in 2024 [4]. - The company expects sequential-quarter revenue growth in Q1 2026 and full-year profitability due to new reimbursement codes and a diversified customer base [3].

Financial Performance - Revenues for the three months ended September 30, 2025 were $6.9 million, a decrease of $1.9 million, or 21.6%, compared to $8.8 million for the same period in 2024 [105] - For the nine months ended September 30, 2025, revenues were $22.5 million, a decrease of $6.2 million, or 21.6%, from $28.7 million in the same period in 2024 [113] - Gross profit for the three months ended September 30, 2025 was $2.7 million, a decrease of $2.5 million, or 48.1%, with a gross profit percentage of 39.1% compared to 59.1% in the prior year [107] Expenses - Research and development expenses increased to $1.8 million for the three months ended September 30, 2025, up $0.9 million, or 100.0%, compared to $0.9 million in the same period in 2024 [110] - Total operating expenses for the three months ended September 30, 2025 were $5.3 million, an increase of $1.5 million, or 40.1%, compared to $3.7 million in the same period in 2024 [104] - Selling and marketing expenses increased to $5.1 million for the nine months ended September 30, 2025, up $1.5 million, or 41.7%, from $3.6 million in the same period in 2024 [117] Cash Flow - Net cash provided by operating activities for the nine months ended September 30, 2025 was $2.7 million, compared to a net cash used of $0.004 million in the same period in 2024 [129] - Net cash provided by operating activities was $2.7 million for the nine months ended September 30, 2025, consisting of a net loss of $4.6 million and non-cash activity of $0.9 million, offset by a decrease in net operating assets of $8.2 million [130] - Net cash used in investing activities for the nine months ended September 30, 2025 reflected $38 thousand of purchases of property and equipment, compared to $0.6 million for the same period in 2024 [131] - Net cash used in financing activities for the nine months ended September 30, 2025 reflected $0.3 million of repurchases of common stock, while the previous year showed $34 thousand of exercised stock options [132] Balance Sheet - Cash and cash equivalents increased to $24.5 million at September 30, 2025, compared to $22.1 million at December 31, 2024, an increase of $2.4 million [122] - Accounts receivable decreased to $9.3 million at September 30, 2025, down $10.4 million from $19.7 million at December 31, 2024, due to reduced sales [123] Taxation - The effective tax rate for the three months ended September 30, 2025 was 60.9%, up from 31.5% in the prior year, primarily due to increased estimated tax credits [112] Economic Factors - The company experienced inflationary pressures due to increased commodity and shipping prices, as well as rising energy and labor costs, prompting actions to minimize effects on product costs [133] Management Insights - Management identified revenue recognition policies as critical to understanding the financial condition and results of operations [136]

Core Insights - Sensus Healthcare, Inc. reported an EPS of -$0.06, outperforming the expected -$0.11 and achieving a positive surprise of 50% [1][5] - The company's quarterly revenue reached $6.9 million, exceeding the estimated $6.3 million and surpassing the Zacks Consensus Estimate by 48.36% [2][5] - Despite a decline from $8.84 million in the same quarter last year, Sensus Healthcare has exceeded consensus revenue estimates in three of the last four quarters [2] Financial Metrics - The company has a negative price-to-earnings (P/E) ratio of approximately -67.74, indicating current losses [3] - The price-to-sales ratio is about 1.54, suggesting investors are paying $1.54 for every dollar of sales, which is considered reasonable [3] - The enterprise value to sales ratio stands at approximately 0.97, indicating a low valuation relative to sales [3] - The enterprise value to operating cash flow ratio is around 10.18, reflecting its valuation in relation to cash flow from operations [4] - Sensus Healthcare has a negative earnings yield of approximately -1.48% [4] - The company maintains a strong financial position with a debt-to-equity ratio of about 0.011, indicating minimal debt [4] - A robust current ratio of approximately 8.14 highlights the company's ability to cover short-term liabilities with short-term assets [4][5]

Core Insights - Sensus Healthcare, Inc. reported a quarterly loss of $0.06 per share, which was better than the Zacks Consensus Estimate of a loss of $0.12, representing an earnings surprise of +50.00% [1] - The company generated revenues of $6.88 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 48.36%, although this is a decline from $8.84 million in the same quarter last year [2] - Sensus Healthcare shares have decreased by approximately 46.7% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $6.04 million, and for the current fiscal year, it is -$0.43 on revenues of $26.34 million [7] - The estimate revisions trend for Sensus Healthcare was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Sensus Healthcare belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Financial Data and Key Metrics Changes - Revenues for Q3 2025 were $6.9 million, down from $8.8 million in Q3 2024, primarily due to a lower number of units sold [14] - Gross profit decreased to $2.7 million with a gross margin of 39.1%, compared to $5.2 million and 59.1% in the prior year [14][15] - The company reported a net loss of $0.9 million, or $0.06 per share, compared to net income of $1.2 million, or $0.07 per diluted share in Q3 2024 [16] Business Line Data and Key Metrics Changes - The company shipped 16 SRT systems in Q3 2025, including three to China, bringing total global sales to over 900 systems since the launch of the SRT platform [5][6] - FDA treatment volumes increased by 20% from Q2 2025, marking the third consecutive quarter of double-digit growth [6][10] - Treatment volumes have increased by 157% since the launch of the Fair Deal Agreement program late last year [6] Market Data and Key Metrics Changes - The introduction of dedicated CPT codes for superficial radiotherapy has increased reimbursement per fraction by over 300% [4][8] - The company anticipates strong interest and rising demand for SRT technology following the new coding [4][10] Company Strategy and Development Direction - The company is focused on expanding its Fair Deal Agreement program and enhancing its software platform, Sentinel, to support long-term revenue growth [11][12] - An expanded R&D program for the next generation of the Sentinel platform, called Sentinel 2.0, is underway, with initial results expected in 2026 [12] - International expansion is a priority, with shipments to China and plans for regulatory clearance in other key markets [13][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future of SRT technology, citing strong patient demand and the importance of the new reimbursement codes [9][22] - The company believes that the clarity provided by the new coding will lead to increased sales and utilization of SRT systems [64] - Management anticipates that pent-up demand will drive sales in Q4 2025, potentially leading to break-even or profitability [32][33] Other Important Information - The company ended Q3 2025 with $24.5 million in cash and no debt, maintaining a strong inventory of approximately $13 million in finished goods [20] - The management acknowledged the passing of a board member, emphasizing the importance of teamwork in navigating recent challenges [21] Q&A Session Summary Question: Impact of LCD reimbursement for ultrasound-guided SRT system - Management indicated that the impact has been minimal due to the significant increase in fractionation reimbursement codes [25][26] Question: Utilization trend metrics - Utilization increased by 20% from Q2 to Q3 2025, with a year-to-date increase of 152% [30] Question: Acceleration of placements in Q4 - Management noted pent-up demand and expected clarity on reimbursement codes would lead to increased placements in Q4 [32] Question: Shift between SRT-100 and SRT-100 Vision - Management believes there will be an uptick in SRT-100 sales, while the Vision product will maintain its importance due to its operating system, Sentinel [39][40] Question: Anticipated ramp for international sales - Management expects international sales to grow to about 20% of total revenue over the next 12-24 months [68]